Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 0904-7488

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 0904-7488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 00)

This is a prescription medication for Venlafaxine Hydrochloride Extended-Release Capsules USP, each capsule equivalent to 150 mg of Venlafaxine. The usual dosage and storage instructions are provided, and it is advisable to keep this medication out of the reach of children. The packaging is designed for institutional use only. Manufactured by MAJOR PHARMACEUTICALS, this product is distributed from Indianapolis, USA.*

FDA Label Image

75mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 01)

This text provides information about Venlafaxine Hydrochloride Extended-Release Capsules in a unit dose package. It includes details such as the NDC code, dosage instructions, storage conditions, precautions, and warnings. The capsules contain 75mg of Venlafaxine hydrochloride USP. It also mentions that the package is not child resistant and is intended for institutional use. The product is distributed by Major Pharmaceuticals.*

FDA Label Image

37.5mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 02)

This is a description of Venlafaxine Hydrochloride Extended-Release Capsules USP containing 100 capsules in a unit dose package by Major Pharmaceuticals. Each capsule contains Venlafaxine Hydrochloride equivalent to 375 mg. The usual dosage and storage instructions are provided. The medication guide is included, and caution is advised to keep the drugs out of reach of children. The package is not child-resistant and is for institutional use only. The product is from NDC 5862-527 by Aurbinda Pharma Limited, packaged and distributed by Major Pharmaceuticals in Indianapolis, USA.*

FDA Label Image

Figure (Venlafaxine Fig1)

FDA Label Image

Figure (Venlafaxine Fig2)

This is a list of interacting drugs and their PK fold change with 90% confidence intervals. The mention of medicines like Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, and Lithium indicates a potential focus on drug interactions and their impact on pharmacokinetics. The text also refers to changes relative to a reference value, suggesting a comparison in drug effectiveness or metabolism.*

FDA Label Image

Figure (Venlafaxine Fig3)

This text seems to be a list of interacting drugs and analytes, along with PK (pharmacokinetic) parameters like Cmax (maximum concentration of a drug) and AU (area under the curve). It also includes information about fold change and 90% CI (confidence interval). The drugs listed include ethanol, aprazolam, indinavir, metoprolol, risperidone, haloperidol, caffeine, tolbutamide, and lithium. Additionally, the analytes mentioned are ethanol, diazepam, desmetyldiazepam, alprazolam, indinavir, metoprolol, imipramine, desipramine, and haloperidol. The information provided in this text can be used to evaluate drug interactions and pharmacokinetics.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.